Neurocrine gets U.S. nod for Parkinson’s therapy; COVID-19 delays launch

Neurocrine gets U.S. nod for Parkinson’s therapy; COVID-19 delays launch
Neurocrine Biosciences Inc said on Monday its add-on treatment for patients with Parkinson's disease received U.S. approval, but the launch will be delayed until later this year because of disruptions ... read more
Source: Bing NewsPublished on 2020-04-27